

Rapid communication

Altered response to benzodiazepine anxiolytics
in mice lacking GABA_{B(1)} receptors

Cedric Mombereau, Klemens Kaupmann, Herman van der Putten, John F. Cryan*

Neuroscience Research, Novartis Institutes for BioMedical Research WSJ 386.344, Novartis Pharma AG., Basel, CH-4002, Switzerland

Received 16 June 2004; accepted 22 June 2004

Available online 24 July 2004

Abstract

Recently, we demonstrated that mice lacking the GABA_{B(1)} subunit were more anxious than wild-type animals in several behavioural paradigms, most notably in the light–dark test. In an attempt to assess the effects of classical benzodiazepine anxiolytics on anxiety-like behaviour observed in these mice, animals were administered either chlordiazepoxide (10 mg/kg, p.o.) or diazepam (7.5 mg/kg, p.o.) prior to testing in the light–dark box. Surprisingly, in contrast with the wild-type mice, neither benzodiazepines decreased anxiety-like behaviour in GABA_{B(1)}^{−/−} mice. These data suggest that targeted deletion of GABA_{B(1)} subunit alters GABA_A receptor function in vivo.

© 2004 Elsevier B.V. All rights reserved.

Keywords: Anxiety; GABA_B; Anxiolytics

γ-Aminobutyric acid (GABA) is the main inhibitory neurotransmitter in the mammalian central nervous system (CNS) and plays a key role in many physiological and psychological processes. There are two different classes of GABA receptors: ionotropic GABA_A receptor and metabotropic GABA_B receptor. The GABA_B receptor is a heterodimer made up of two subunits, GABA_{B(1)} and GABA_{B(2)}, both necessary for GABA_B receptors to be functionally active. Although, it is well known that GABA is involved in the pathophysiology of anxiety, the role of the GABA_B receptor in anxiety is still unclear. The recently generated GABA_{B(1)} knockout mice offer a new and useful tool to elucidate the role of GABA_B receptors in psychiatric disorders. We recently demonstrated that targeted deletion of GABA_{B(1)} subunit increased anxiety in the light–dark box (decreased number of transitions). In an attempt to understand the processes involved in this hyperanxious phenotype, and to assess whether these anxious mice may represent a model to assess anxiolytic activity, we administered classical benzodiazepine anxiolytics, ligands of GABA_A, to wild-type and GABA_{B(1)}^{−/−} mice (Fig. 1).

The GABA_{B(1)}^{−/−} mice were generated on a BALB/c background as described previously (Schuler, 2001). Both male and female animals (8–12 weeks old) were used in this age- and sex-matched study (~equal in number). Mice were housed in groups of one to three at room temperature on a 12-h light–dark cycle (lights on 06:00) with food and pellets available ad libitum. The light–dark box test was carried out as described previously (Mombereau et al., 2004). Briefly, the apparatus consisted of a clear plexiglass cage (44×21×21 cm) separated into two compartments by a partition, which had a small opening (12×5 cm) at floor level. The open compartment was open topped made of transparent plexiglass and brightly illuminated by a 60-W desk lamp overhead (approximately 1000 Lux). The smaller compartment was 14 cm long and the cover on top all made from black plexiglass. Mice were injected with chlordiazepoxide (10 mg/kg, p.o.) or diazepam (7.5 mg/kg, p.o.) or methycellulose, 1 h prior to behavioural testing. Doses were selected from previous data showing robust anxiolytic effects at these doses in normal mice (Cryan, unpublished observations). Subsequently, mice were individually placed in the centre of the brightly lit

* Corresponding author. Tel.: +41 61 3247489; fax: +41 61 3244502.
E-mail address: john_f.cryan@pharma.novartis.com (J.F. Cryan).




Fig. 1. Blunted anxiolytic effect of benzodiazepines in GABA_{B(1)}^{-/-} mice. Acute administration of diazepam (7.5 mg/kg, p.o.) and chlordiazepoxide (CDZ, 10 mg/kg, p.o.) increased the number of transitions in GABA_{B(1)}^{+/+} mice. $n=10$ –11 per treatment group. These two treatments did not affect the number of transitions in GABA_{B(1)}^{-/-} mice. $n=10$ –11 per treatment group. All bars represent mean values with vertical lines indicating 1 S.E.M. *Groups that differed significantly to vehicle-treated GABA_{B(1)}^{+/+} mice ($P<0.05$).

compartment, facing away from the partition and allowed to freely explore the apparatus for 10 min. The apparatus was cleaned thoroughly between subjects. The number of light–dark transitions, time spent in the light compartment, and latency to enter dark were recorded by a trained observer, transitions being the most reliable indicator of anxiety-like behavior in the test (Crawley and Davis, 1982; Holmes, 2001). The results were statistically evaluated using two-way Analysis of Variance (ANOVA), which was then followed by appropriate Fisher's post hoc test. As previously reported (Mombereau et al., 2004), many GABA_{B(1)}^{-/-} mice froze upon being placed in the apparatus (30% in vehicle-treated animals), which was not decreased by drug treatment. In addition, as previously described, GABA_{B(1)}^{-/-} mice displayed lower number of transitions than their wild-type counterparts, although this did not reach statistical significance on this occasion ($P=0.16$). On examination of the number of transitions, ANOVA revealed an effect of genotype [$F(1,58)=6.623$, $P=0.013$], treatment [$F(2,58)=3.283$, $P=0.045$], but no genotype \times treatment interaction [$F(2,58)=0.829$, $P=0.442$]. Post hoc analysis indicated that diazepam or chlordiazepoxide increased significantly the number of transitions in wild-type mice, but this effect was markedly blunted in GABA_{B(1)}^{-/-} mice.

This study demonstrated that the selective ablation of GABA_{B(1)} subunit abolished the response to benzodiaze-

pin in the light–dark box test. This suggests a functional relationship between both GABA_B and GABA_A receptors in vivo. Further studies are required to assess if the absence of anxiolytic effect are caused by alterations in benzodiazepine binding and/or GABA_A subunit expression, as is the case with the 5-HT_{1A} receptor knockout (Sibille et al., 2000). Furthermore, we cannot exclude that this lack of efficiency of chlordiazepoxide and diazepam is due to an interaction between loss of GABA_B receptor function and the background strain employed (Lepicard et al., 2000). In summary, given the fact that classical anxiolytics are not able to reduce anxiety in GABA_{B(1)}^{-/-} mice, this may not be a useful model to assess the anxiolytic potential of novel compounds or to assess the in vivo selectivity of novel anxiolytics acting at GABA_B receptors such as GABA_B receptor-positive modulators (Mombereau et al., 2004).

Acknowledgements

We sincerely thank Christine Hunn, Hugo Buerki, and Gilles Sansig for the excellent technical assistance. CM is a doctoral student affiliated with the Laboratoire de Neuroscience Cognitives, CNRS UMR 5106, Université de Bordeaux 1, Avenue des Facultés, Talence cedex 33405, France. JFC and KK are supported by the National Institutes of Mental Health/National Institute on Drug Abuse grant U01 MH69062.

References

- Crawley, J.N., Davis, L.G., 1982. Baseline exploratory activity predicts anxiolytic responsiveness to diazepam in five mouse strains. *Brain. Res. Bull.* 8, 609–612.
- Holmes, A., 2001. Targeted gene mutation approaches to the study of anxiety-like behavior in mice. *Neurosci. Biobehav. Rev.* 25, 261–273.
- Lepicard, E.M., Joubert, C., Hagneau, I., Perez-Diaz, F., Chapouthier, G., 2000. Differences in anxiety-related behavior and response to diazepam in BALB/cByJ and C57BL/6J strains of mice. *Pharmacol. Biochem. Behav.* 67, 739–748.
- Mombereau, C., Kaupmann, K., Froestl, W., Sansig, G., van der Putten, H., Cryan, J.F., 2004. Genetic and pharmacological evidence of a role for GABA_B Receptors in the modulation of anxiety and antidepressant-like behavior. *Neuropsychopharmacology* 29 (6), 50–62.
- Sibille, E., Pavlides, C., Benke, D., Toth, M., 2000. Genetic inactivation of the Serotonin(1A) receptor in mice results in downregulation of major GABA(A) receptor alpha subunits, reduction of GABA(A) receptor binding, and benzodiazepine-resistant anxiety. *J. Neurosci.* 20, 2758–2765.